GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Liabilities-to-Assets

Mymetics (Mymetics) Liabilities-to-Assets : 754.75 (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Mymetics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Mymetics's Total Liabilities for the quarter that ended in Sep. 2023 was $80.76 Mil. Mymetics's Total Assets for the quarter that ended in Sep. 2023 was $0.11 Mil. Therefore, Mymetics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 754.75.


Mymetics Liabilities-to-Assets Historical Data

The historical data trend for Mymetics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Liabilities-to-Assets Chart

Mymetics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.02 7.49 7.84 8.87 9.87

Mymetics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.57 9.87 10.11 140.80 754.75

Competitive Comparison of Mymetics's Liabilities-to-Assets

For the Biotechnology subindustry, Mymetics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mymetics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Mymetics's Liabilities-to-Assets falls into.



Mymetics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Mymetics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=76.501/7.755
=9.86

Mymetics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=80.758/0.107
=754.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mymetics  (OTCPK:MYMX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Mymetics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Mymetics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mymetics (Mymetics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066
Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.
Executives
Marcel B. Ruegg director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard officer: President, CEO, CFO ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering director, officer: President and CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin officer: CEO 40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann officer: CSO KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern director 815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin director POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury officer: CSO CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd. 10 percent owner C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd 10 percent owner ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet director, officer: CEO 14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer director, officer: vp corp development
Ernst Lubke director, officer: CFO 39, ROUTE D'ARZIER, ARZIER V8 CH-1273